Gufic Biosciences growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+15.2%	—
EBITDA	+12.4%	—
Net Income	−7.8%	—
EPS (adj.)	−7.8%	—
Total Assets	+14.8%	+15.9%
Total Equity	+10.6%	+24.1%
Free Cash Flow	−70.7%	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GUFICBIO₹423.75

Gufic Biosciences Limited

· Pharma & Health

₹ CrorePeersRPGLIFE UNICHEMLAB GUJTHEM ORCHPHARMA SMSPHARMA INDSWFTLAB FDC IOLCPMcap ₹4,249 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+15.2	—
EBITDA	+12.4	—
Net Income	-7.8	—
EPS (adj.)	-7.8	—
Total Assets	+14.8	+15.9
Total Equity	+10.6	+24.1
Free Cash Flow	-70.7	—

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.